Common use of Termination for Receipt of Not Approvable Letter Clause in Contracts

Termination for Receipt of Not Approvable Letter. In the event ------------------------------------------------ GSK receives a not approvable letter from the FDA pursuant to 21 C.F.R. (S) 314.120 for the OBD Chronic Product, GSK shall promptly notify Adolor of the receipt of such not approvable letter and, during the sixty (60) days after notice of receipt of such not approvable letter, have the right to terminate this Agreement with respect to the OBD Chronic Product in both the United States and the ROW upon one hundred twenty (120) days prior written notice to Adolor. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.1, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic Product, and remain subject to its obligations, under this Agreement.

Termination for Receipt of Not Approvable Letter. In the event ------------------------------------------------ GSK Adolor receives a not approvable letter from the FDA pursuant to 21 C.F.R. (S) 314.120 C.F.R.(S)314.120 for the OBD Chronic POI Product, GSK Adolor shall promptly notify Adolor GSK of the receipt of such not approvable letter andand GSK shall, during the sixty (60) days after notice of receipt of such not approvable letter, have the right to terminate this Agreement with respect to the OBD Chronic Product all Adolor Products in both the United States and the ROW upon one hundred twenty (120) days prior written notice to Adolor. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.116.5.1, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic ProductProducts, and remain subject to its obligations, under this Agreement.

Termination for Receipt of Not Approvable Letter. In the event ------------------------------------------------ GSK Adolor receives a not approvable letter from the FDA pursuant to 21 C.F.R. (S) 314.120 C.F.R.(S)314.120 for the OBD Chronic Product**, GSK Adolor shall promptly notify Adolor GSK of the receipt of such not approvable letter andand GSK shall, during the sixty (60) days after notice of receipt of such not approvable letter, have the right to terminate this Agreement with respect to the OBD Chronic Product all ** in both the United States and the ROW upon one hundred twenty (120) days prior written notice to Adolor. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.116.5.1, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic Product**, and remain subject to its obligations, under this Agreement.

Termination for Receipt of Not Approvable Letter. In the event ------------------------------------------------ GSK receives a not approvable letter from the FDA pursuant to 21 C.F.R. (S) 314.120 for the OBD Chronic Product**, GSK shall promptly notify Adolor of the receipt of such not approvable letter and, during the sixty (60) days after notice of receipt of such not approvable letter, have the right to terminate this Agreement with respect to the OBD Chronic Product ** in both the United States and the ROW upon one hundred twenty (120) days prior written notice to Adolor. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.1, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic Product**, and remain subject to its obligations, under this Agreement.